News Trial of Bundibugyo Ebola drugs starts in DRC Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.
News WHO names three 'priority' Ebola drugs for trials The WHO has named drugs from Regeneron, Mapp Bio, and Gilead that should be fast-tracked through trials to respond to the current Ebola outbreak.
News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.